Cercar
01/05/2026
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer
Gillessen, S, Gallardo, E, Choudhury, A, Saad, F, Soares, A, Loriot, Y, McDermott, R, Rodriguez-Vida, A, Velho, PI, Nolè, F, Cruz, F, Roumeguere, T, Daugaard, G, Yamamura, R, Bompas, E, Maroto, P, Veiga, FG, Skoneczna, I, da Trindade, KM, Carcano, FM, Lecouvet, F, Coens, C, Poncet, C, Fournier, B, Tombal, B. Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer. ANNALS OF ONCOLOGY. 2026; 37(5)DOI:10.1016/j.annonc.2026.02.009. PMID:41763609. IF:65.400(Q1/1D).
19/04/2026
Progression-Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort
Yaringaño, J, Mirallas, O, Navarro, V, Gómez-Puerto, D, Velilla, G, Vaz, MA, Gorria, T, Martínez-Monino, A, Hernández, A, Aguado, M, Di Muzio, A, Valbuena, DL, Ruiz-Pace, F, González, M, Martínez-García, M, Villacampa, G, Balaña, C, Carles, J, Dienstmann, R, Pineda, E, Sepúlveda, JM, Vieito, M. Progression-Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort. Cancer Medicine. 2026; 15(4)DOI:10.1002/cam4.71825. PMID:42002922. IF:3.100(Q2/5D).
28/04/2026
Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy
Gámez-Pozo, A, Trilla-Fuertes, L, Becerril-Gómez, F, Lalanda-Delgado, P, Soriano, V, Goldaraz, FG, Lecumberri, MJ, de la Borbolla, MR, Majem, M, Pérez-Ruiz, E, González-Cao, M, Oramas, J, López-Vacas, R, Magdaleno, A, Fra, J, Martín-Carnicero, A, Corral, M, Puértolas, T, Ramos-Ruiz, R, Espinosa, E, Vara, JAF. Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; 75(5)DOI:10.1007/s00262-026-04392-1. PMID:42047827. IF:5.100(Q1/3D).
01/03/2026
Impact of Cell-Free TNA Fraction on Analytical Success in Liquid Biopsy for Lung Adenocarcinoma: Experience from a Tertiary Hospital
Herrera, IC, Cols, LC, Pijuan-Andujar, L, Cajo, SA, Montalvan, RG, Calvente, MG, Luque, GA, Gallardo, A, Jaramillo, JFC. Impact of Cell-Free TNA Fraction on Analytical Success in Liquid Biopsy for Lung Adenocarcinoma: Experience from a Tertiary Hospital. LABORATORY INVESTIGATION. 2026; 106(3)DOI:10.1016/j.labinv.2025.105990. PMID:. IF:4.200(Q1/1D).
01/07/2026
Mullerian adenosarcoma of the uterus, ovary and peritoneum: Whole transcriptomic digital spatial profiling (DSP) in a cohort of 42 tumors
D'Angelo, E, Kingsley, LG, Espinosa, I, Cipriani, V, Marotta, A, Nasr, S, Zdravkovic, S, Howitt, BE, Prat, J. Mullerian adenosarcoma of the uterus, ovary and peritoneum: Whole transcriptomic digital spatial profiling (DSP) in a cohort of 42 tumors. HUMAN PATHOLOGY. 2026; 173DOI:10.1016/j.humpath.2026.106117. PMID:41932512. IF:2.600(Q2/4D).
01/03/2026
Serous Tubal Intraepithelial Carcinoma (STIC): Incidence and Clinical Implications in 254 Consecutive Cases from a Tertiary Care Hospital
Misad, C, Cajo, SA, Espadaler, I, Muñoz, R, D'Angelo, E, Gallardo, A, Espinosa, I, Prat, J. Serous Tubal Intraepithelial Carcinoma (STIC): Incidence and Clinical Implications in 254 Consecutive Cases from a Tertiary Care Hospital. LABORATORY INVESTIGATION. 2026; 106(3)DOI:10.1016/j.labinv.2025.105314. PMID:. IF:4.200(Q1/1D).
01/02/2026
Cardiac plasmacytoma with extensive infiltration: multimodal diagnosis and therapeutic challenges: a case report
Rodríguez-Fraga, P, Cascos, E, Cuartas, A, Espadaler, I. Cardiac plasmacytoma with extensive infiltration: multimodal diagnosis and therapeutic challenges: a case report. European Heart Journal-Case Reports. 2026; 10(2)DOI:10.1093/ehjcr/ytag102. PMID:41728229. IF:(Q/D).
01/03/2026
ctDNA clearance after induction therapy as predictor of response to radical chemoradiotherapy in locally advanced head and neck cancer
Bruixola, G, Martín-Arana, J, Vidales, Z, Peon, G, Gimeno-Valiente, F, Tous, S, Camblor, DG, Cirauqui, B, García-Bartolomé, M, Sumarroca, A, Martínez-Castedo, B, Leon, X, Micó-García, B, Iglesias-Martínez, B, García-March, A, Segui, V, Pavón, MA, Quirós, B, Clavero, O, Maroñas, M, Escorihuela-Garcia, V, Tarazona, N, Alemany, L, Oliva, M. ctDNA clearance after induction therapy as predictor of response to radical chemoradiotherapy in locally advanced head and neck cancer. RADIOTHERAPY AND ONCOLOGY. 2026; 216DOI:. PMID:. IF:5.300(Q1/2D).
01/06/2026
Artificial Intelligence-Assisted reflectance confocal microscopy for Real-Time intraoperative margin assessment in oral squamous cell carcinoma
Hosseinzadeh, F, Zanoni, D, França, PDD, Valero, C, Peterson, G, Ardigo, M, Ghossein, R, Dusza, SW, Pillarsetty, N, Kose, K, Wong, RJ, Ganly, I, Rajadhyaksha, M, Patel, SG. Artificial Intelligence-Assisted reflectance confocal microscopy for Real-Time intraoperative margin assessment in oral squamous cell carcinoma. ORAL ONCOLOGY. 2026; 177DOI:10.1016/j.oraloncology.2026.107939. PMID:41932031. IF:3.900(Q1/2D).
01/03/2025
Lower lip reconstruction with the Karapandzic flap or the Colmenero flap: Description of results
Sumarroca, A, Vega, C, López, S, Leidinger, A, Pedemonte, G, León, X, Costa-González, JM. Lower lip reconstruction with the Karapandzic flap or the Colmenero flap: Description of results. Acta Otorrinolaringologica Espanola. 2025; 76(2)DOI:10.1016/j.otorri.2024.10.001. PMID:39923991. IF:(Q/D).
01/03/2026
Cochlear implant failures and complications: What should radiologists look for?
Moreno, EG, Pizarro, MPV, Dotu, CO, Martínez, AL, Escalante, JEM, Beltran, JD. Cochlear implant failures and complications: What should radiologists look for?. Radiologia. 2026; 68(2)DOI:10.1016/j.rx.2025.501685. PMID:. IF:(Q/D).
01/04/2026
Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with ?-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma
Schjesvold, F, Spencer, A, Cohen, YC, Ocio, EM, Lopez-Pardo, J, Cafro, AM, Callander, NS, Kaufman, JL, Mohan, M, Wermke, M, Doki, N, Kan, RBC, Milanez-Almeida, P, Stein, A, Trabucco, G, Ye, S, Kulec, K, Sechaud, R, Banerjee, S, Zhong, HQ, Lai, CT, Rauch, PJ, Raab, MS. Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with ?-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma. CANCER. 2026; 132(7)DOI:10.1002/cncr.70341. PMID:41880322. IF:5.100(Q1/3D).
01/05/2026
Incidence and outcome of hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMT
Cesaro, S, Garonzi, C, Tridello, G, Verheggen, I, Liu, DH, Flynn, C, Alahmari, A, Kaynar, L, Rabitsch, W, Uygun, V, Chorao, P, Hu, J, Esquirol, A, Piñana, JL, Aljurf, M, Wagner-Drouet, E, Lang, PT, Martin-Sanchez, G, Ratip, S, Facchini, L, Nasilowska-Adamska, B, Styczynski, J, Ram, R, Metafuni, E, Tanase, A, Kalwak, K, Serio, B, Hashem, H, Castagna, L, Vicent, MG, Karakukcu, M, Halahleh, K, Baltadakis, I, Benedetti, E, Mikulska, M, de la Camara, R, Averbuch, D. Incidence and outcome of hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMT. BONE MARROW TRANSPLANTATION. 2026; 61(5)DOI:10.1038/s41409-026-02832-1. PMID:41888297. IF:5.200(Q1/1D).
01/04/2026
Evolving Patterns of EBV-Associated PTLD After Allogeneic Stem Cell Transplantation: Frequency, Characteristics and Outcomes in a Multicenter GETH-TC Study
García-Cadenas, I, Guerreiro, M, Yañez, L, Chorao, P, Martin, F, Suárez-Lledó, M, Pérez, A, Tomás, LG, López, J, Marsal, J, Romero, N, Huguet, M, Zabalza, A, González-Vicent, M, Vázquez, L, Silva, P, Gil, D, Micó-Cerdà, M, Sánchez, P, Filaferro, S, Balsalobre, P, Jiménez-Ubieto, A, Martino, R, Piñana, JL. Evolving Patterns of EBV-Associated PTLD After Allogeneic Stem Cell Transplantation: Frequency, Characteristics and Outcomes in a Multicenter GETH-TC Study. EUROPEAN JOURNAL OF HAEMATOLOGY. 2026; 116(4)DOI:10.1111/ejh.70109. PMID:41502050. IF:2.300(Q2/5D).
01/04/2026
Length of SARS-CoV-2 shedding in HCT recipients: an Infectious Disease Working Party of EBMT study
Mikulska, M, Tridello, G, Ljungman, P, Styczynski, J, Averbuch, D, Cesaro, S, Knelange, N, Wendel, L, Piñana, JL, Popova, M, Kröger, N, Sengeloev, H, Besley, C, Labussiere-Wallet, H, Yegin, ZA, Greco, R, Baron, F, Yonal-Hindilerden, I, Xhaard, A, Metafuni, E, Verbeek, M, Byrne, J, Toprak, SK, Grassi, A, Vallisa, D, Clay, J, Bufarull, RM, Van Gorkom, G, Sevindik, OG, Wilson, K, de la Camara, R. Length of SARS-CoV-2 shedding in HCT recipients: an Infectious Disease Working Party of EBMT study. BONE MARROW TRANSPLANTATION. 2026; 61(4)DOI:10.1038/s41409-026-02819-y. PMID:41795056. IF:5.200(Q1/1D).
01/06/2026
Pomalidomide, Cyclophosphamide and Dexamethasone (PCd): Outcomes in Patients With Double- or Triple-Refractory Multiple Myeloma
Hidalgo-Soto, M, Rodríguez-Lobato, LG, Borrella, CM, Cayuela, AS, Pardo, JL, Rosiñol, L, Cibeira, MT, García-Guiñon, A, Tolosa-Ridao, C, Arostegui, IC, Sureda, A, Herranz, MJ, Montreal, EA, Pelicano, M, Alzuria, YB, Sansa, MC, Gironella, M, González, Y, De Larrea, CF. Pomalidomide, Cyclophosphamide and Dexamethasone (PCd): Outcomes in Patients With Double- or Triple-Refractory Multiple Myeloma. EUROPEAN JOURNAL OF HAEMATOLOGY. 2026; 116(6)DOI:10.1111/ejh.70126. PMID:41652820. IF:2.300(Q2/5D).
01/01/2024
Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study
Habib, AA, Sacconi, S, Antonini, G, Cortés-Vicente, E, Grosskreutz, J, Mahuwala, ZK, Mantegazza, R, Pascuzzi, RM, Utsugisawa, K, Vissing, J, Vu, T, Wiendl, H, Boehnlein, M, Greve, B, Woltering, F, Bril, V. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. Therapeutic Advances in Neurological Disorders. 2024; 17DOI:10.1177/17562864241273036. PMID:39297052. IF:4.100(Q1/2D).
01/05/2026
Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. Consensus of the Spanish Society of Neurology's Study Group on Multiple Sclerosis and Related Neuroimmune Diseases
Domínguez, JMG, Villar, LM, Arrambide, G, Blanco, Y, Calles, MC, Casanova, B, Castillo-Triviño, T, França, LCF, Eichau, S, Pérez, MAH, Landete, L, Lallana, JM, Oreja-Guevara, C, Prieto, JM, Querol, L, Caminero, AB. Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. Consensus of the Spanish Society of Neurology's Study Group on Multiple Sclerosis and Related Neuroimmune Diseases. NEUROLOGIA. 2026; 41(4)DOI:10.1016/j.nrl.2025.501928. PMID:. IF:3.100(Q2/4D).
04/04/2026
Brachio-cervical inflammatory myopathy: multilevel clinical, histopathological and multi-omic analyses of a syndrome variably associated with systemic sclerosis
Kleefeld, F, Gamboa, JT, Pinal-Fernandez, I, Preusse, C, Nelke, C, Goebel, HH, Mensch, A, Mossakowski, A, Miah, MU, Diaz-Manera, J, Torchia, E, Bortolani, S, Hentschel, A, Funke, A, Souvannanorath, S, Authier, FJ, Malfatti, E, Gehrig, J, Mammen, AL, Casal-Dominguez, M, De Winter, J, De Ridder, W, Ruck, T, Schneider, U, Roos, A, Gallardo, E, Tasca, G, Stenzel, W. Brachio-cervical inflammatory myopathy: multilevel clinical, histopathological and multi-omic analyses of a syndrome variably associated with systemic sclerosis. ACTA NEUROPATHOLOGICA. 2026; 151(1)DOI:10.1007/s00401-026-03006-5. PMID:41934478. IF:9.300(Q1/1D).
01/04/2026
Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis
Cortés-Vicente, E, Guerrero, A, Díaz, C, Martínez, E, Toja-Camba, FJ, Abad, MR, Serra, JM, Trillo, JL, Machín, CM, Gil, A. Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis. ADVANCES IN THERAPY. 2026; 43(4)DOI:10.1007/s12325-026-03490-x. PMID:41591648. IF:4.000(Q1/3D).